The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy

Emma Harris, Ana Tiganescu, Sandy Tubeuf, Sarah Louise Mackie

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Glucocorticoids are often required for adequate control of inflammation in many serious inflammatory diseases; common indications for long-term treatment include polymyalgia rheumatica, giant cell arteritis, asthma and chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is, however, associated with many adverse effects involving skin, gastro-intestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and neuropsychiatric systems. This balance between benefits and risks of glucocorticoids is important for clinical practice and glucocorticoid-related adverse effects can significantly impair health-related quality of life. Understanding the nature and mechanisms of glucocorticoid-related adverse effects may inform how patients are monitored for toxicity and identify those groups, such as older people, that may need closer monitoring. For clinical trials in diseases commonly treated with glucocorticoids, standardised measurement of glucocorticoid-related adverse effects would facilitate future evidence synthesis and meta-analysis.

Original languageEnglish
Article number38
Number of pages10
JournalCurrent Rheumatology Reports
Volume17
Issue number6
DOIs
Publication statusPublished - 23 Apr 2015
Externally publishedYes

Fingerprint

Glucocorticoids
Therapeutics
Polymyalgia Rheumatica
Giant Cell Arteritis
Chronic Obstructive Pulmonary Disease
Meta-Analysis
Skeletal Muscle
Asthma
Quality of Life
Clinical Trials
Inflammation
Bone and Bones
Skin

Cite this

@article{f5ea1b5010dd4f8d891033b0936df288,
title = "The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy",
abstract = "Glucocorticoids are often required for adequate control of inflammation in many serious inflammatory diseases; common indications for long-term treatment include polymyalgia rheumatica, giant cell arteritis, asthma and chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is, however, associated with many adverse effects involving skin, gastro-intestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and neuropsychiatric systems. This balance between benefits and risks of glucocorticoids is important for clinical practice and glucocorticoid-related adverse effects can significantly impair health-related quality of life. Understanding the nature and mechanisms of glucocorticoid-related adverse effects may inform how patients are monitored for toxicity and identify those groups, such as older people, that may need closer monitoring. For clinical trials in diseases commonly treated with glucocorticoids, standardised measurement of glucocorticoid-related adverse effects would facilitate future evidence synthesis and meta-analysis.",
keywords = "Adverse effects, Giant cell arteritis, Glucocorticoids, Polymyalgia rheumatica",
author = "Emma Harris and Ana Tiganescu and Sandy Tubeuf and Mackie, {Sarah Louise}",
year = "2015",
month = "4",
day = "23",
doi = "10.1007/s11926-015-0513-4",
language = "English",
volume = "17",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "6",

}

The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. / Harris, Emma; Tiganescu, Ana; Tubeuf, Sandy; Mackie, Sarah Louise.

In: Current Rheumatology Reports, Vol. 17, No. 6, 38, 23.04.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy

AU - Harris, Emma

AU - Tiganescu, Ana

AU - Tubeuf, Sandy

AU - Mackie, Sarah Louise

PY - 2015/4/23

Y1 - 2015/4/23

N2 - Glucocorticoids are often required for adequate control of inflammation in many serious inflammatory diseases; common indications for long-term treatment include polymyalgia rheumatica, giant cell arteritis, asthma and chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is, however, associated with many adverse effects involving skin, gastro-intestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and neuropsychiatric systems. This balance between benefits and risks of glucocorticoids is important for clinical practice and glucocorticoid-related adverse effects can significantly impair health-related quality of life. Understanding the nature and mechanisms of glucocorticoid-related adverse effects may inform how patients are monitored for toxicity and identify those groups, such as older people, that may need closer monitoring. For clinical trials in diseases commonly treated with glucocorticoids, standardised measurement of glucocorticoid-related adverse effects would facilitate future evidence synthesis and meta-analysis.

AB - Glucocorticoids are often required for adequate control of inflammation in many serious inflammatory diseases; common indications for long-term treatment include polymyalgia rheumatica, giant cell arteritis, asthma and chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is, however, associated with many adverse effects involving skin, gastro-intestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and neuropsychiatric systems. This balance between benefits and risks of glucocorticoids is important for clinical practice and glucocorticoid-related adverse effects can significantly impair health-related quality of life. Understanding the nature and mechanisms of glucocorticoid-related adverse effects may inform how patients are monitored for toxicity and identify those groups, such as older people, that may need closer monitoring. For clinical trials in diseases commonly treated with glucocorticoids, standardised measurement of glucocorticoid-related adverse effects would facilitate future evidence synthesis and meta-analysis.

KW - Adverse effects

KW - Giant cell arteritis

KW - Glucocorticoids

KW - Polymyalgia rheumatica

UR - http://www.scopus.com/inward/record.url?scp=84938089073&partnerID=8YFLogxK

U2 - 10.1007/s11926-015-0513-4

DO - 10.1007/s11926-015-0513-4

M3 - Article

VL - 17

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 6

M1 - 38

ER -